Vocabria Europska Unija - hrvatski - EMA (European Medicines Agency)

vocabria

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.

Rekambys Europska Unija - hrvatski - EMA (European Medicines Agency)

rekambys

janssen-cilag international nv - rilpivirine - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Rukobia Europska Unija - hrvatski - EMA (European Medicines Agency)

rukobia

viiv healthcare b.v. - fostemsavir trometamol - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant hiv-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Jemperli Europska Unija - hrvatski - EMA (European Medicines Agency)

jemperli

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Xevudy Europska Unija - hrvatski - EMA (European Medicines Agency)

xevudy

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - imuni serumi i homologna, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

INFANRIX IPV 30 i.j./0.5 mL+ 40 i.j./0.5 mL+ 25 µg/0.5 mL+ 25 µg/0.5 mL+ 8 µg/0.5 mL+ 40 AgU/0.5 mL+ ≥ 8 AgU/0.5 mL+ 32 AgU/0.5 Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

infanrix ipv 30 i.j./0.5 ml+ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 8 µg/0.5 ml+ 40 agu/0.5 ml+ ≥ 8 agu/0.5 ml+ 32 agu/0.5

evropa lijek pharma d.o.o. - пропорциональному protiv difterije, pertusisa, poliomijelitisa, tetanusa - suspenzija za injekciju - 30 i.j./0.5 ml+ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 8 µg/0.5 ml+ 40 agu/0.5 ml+ ≥ 8 agu/0.5 ml+ 32 agu/0.5 ml - 0,5 ml suspenzije za injekciju (1 doza) sadrži: min. 30 i.j. toksoida difterije min. 40 i.j. toksoida tetanusa 25 mcg toksoida pertusisa 25 mcg filamentoznog hemaglutinina 8 mcg pertaktina 40 dantigen jedinica polio virusa tip 1 (soj mahoney) 8 dantigen jedinica polio virusa tip 2 (soj mef1) 32 dantigen jedinica polio virusa tip 3 (soj saukett)

FLIXONASE 50 µg/1 doza sprej za nos, suspenzija Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

flixonase 50 µg/1 doza sprej za nos, suspenzija

evropa lijek pharma d.o.o. - flutikazon - sprej za nos, suspenzija - 50 µg/1 doza - 1 doza spreja za nos, suspenzije sadrži: 50 mcg flutikazon propionata

Arexvy Europska Unija - hrvatski - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekcije respiratornih sincicijskih virusa - cjepiva - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Apretude Europska Unija - hrvatski - EMA (European Medicines Agency)

apretude

viiv healthcare b.v. - cabotegravir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 i 5.